David Nutt
Edmond J. Safra Professor of Neuropsychopharmacology
Data updated
Research Footprint
David Nutt appears in 131 tracked papers (2010–2026), most studied alongside Psilocybin, LSD and MDMA, across Depressive Disorders, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: Robin Carhart-Harris, David Erritzoe and Leor Roseman.
Publication Landscape
How the 131 papers Blossom tracks for David Nutt line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has David Nutt's publishing grown?
SourcedTracked papers by publication year; 2 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 131 of 131 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does David Nutt publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does David Nutt publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
David Nutt is an English neuropsychopharmacologist and a leading authority on the effects of drugs on the brain and society. He holds the Edmond J. Safra Chair in Neuropsychopharmacology at Imperial College London and is the founder of Drug Science, an independent body providing evidence-based drug information. His career has focused on addiction, anxiety, and sleep, and he has been a vocal advocate for the therapeutic use of psychedelics and scientific drug policy.
Key Impact
Leading figure in neuropsychopharmacology and drug policy reform; founder of Drug Science.
Collaboration Network
113 collaborators· click a node to visit their profile
Full network →Collaboration Network
See David Nutt's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations David Nutt is associated with.
Imperial College London
academicEdmond J. Safra Professor of Neuropsychopharmacology
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Drug Science
Founder & Chair
Drug Science is a UK-based independent, science-led drugs charity founded in 2010 and headquartered in London, with work aimed at the UK public and international audiences. It focuses on building an evidence base for drug harms and benefits, and on equipping the public, media, and policymakers with scientific information to support sensible drug laws and evidence-based debate. In psychedelics, Drug Science is an explicit field actor rather than a peripheral observer. Its Medical Psychedelics Working Group promotes evidence-based psychedelic research and access, including support for removing psychedelic drugs from Schedule 1 restrictions, improving regulatory pathways for medical use, and producing educational resources for healthcare professionals and the public. The organization also publishes commentary and research-led content on psychedelic policy, clinical development, and public attitudes, and has recent documented activity around psilocybin regulation, psychedelic terminology, and UK research ecosystem updates.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways plc (Nasdaq: CMPS) is a UK-headquartered clinical-stage biopharmaceutical company and the most advanced developer of a classic psychedelic medicine. Its lead asset, COMP360 — a synthetic, proprietary formulation of psilocybin — is being developed for treatment-resistant depression (TRD) delivered alongside a psychological-support model. COMP360 is the first psilocybin programme to complete two positive pivotal Phase 3 trials: COMP005 met its primary endpoint in June 2025 and the confirmatory COMP006 (two fixed doses given three weeks apart) did so in February 2026, with 26-week data reported in July 2026 confirming a rapid and durable antidepressant profile. In April 2026 the FDA granted a rolling NDA submission request and selected COMP360 for the Commissioner's National Priority Voucher programme, which carries a shortened review window. COMPASS has since begun that rolling submission and guides to a potential US launch in the first half of 2027, subject to approval, positioning it as the frontrunner for the first FDA-approved classic psychedelic therapy.
View stakeholder →